glp-1 receptor agonists brand names ANSE1024_0051_table_a.jpg Latin America Glucagon-like Peptide-1 Agonists

Thus, it is necessary to assess cardiovascular outcomes in clinical trials of new antihyperglycemic agents

Canadian Journal of Gastroenterology & Hepatology

Managing Symptoms: These effects are usually mild and tend to fade as your system reaches a steady state. Staying hydrated and eating smaller, more frequent meals can significantly improve comfort

Besides this, increasing awareness of the advantages of these drugs through marketing efforts and direct-to-consumer advertising, particularly on social media, and a favorable regulatory landscape are enabling approvals and boosting demand in the market

doi: 10.1016/j.bbrc.2009.10.054 41 Portela-GomesGMHoogA

Methods In this open-label, single-center, casecontrol pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of 30 kg/m 2 were offered to receive a GLP-1-RA (semaglutide, liraglutide) in addition to the usual care weight management (UCWM)